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of the literature
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Andréa Ribeiro Soares2 and Maria Helena Ornellas1*Abstract
Background: Central nervous system involvement is considered a rare complication of chronic lymphocytic
leukemia, and so there is the risk of being overlooked.
Case presentation: We report a case of central nervous system involvement in a 75-year-old mulatto woman with
chronic lymphocytic leukemia after 5 years of follow-up and a literature review on the subject. The clinical course,
treatment and outcome are described. A systematic, meticulous and comprehensive analysis of existing publications
regarding chronic lymphocytic leukemia with central nervous system involvement was performed.
Conclusion: We concluded that central nervous system involvement of chronic lymphocytic leukemia is probably
not associated with any evident risk factors. Diagnostic approach differs by institutions but often includes imaging,
morphology and flow cytometry. Resolution of central nervous system symptoms can usually be accomplished with
intrathecal chemotherapy or irradiation followed by systemic treatment. The recognition of this entity by clinicians
could lead to early detection and treatment, resulting in better outcomes in this rare complication.
Keywords: Chronic lymphocytic leukemia, Flow cytometry, Central nervous system involvementBackground
B-cell chronic lymphocytic leukemia (B-CLL) occurs in
elderly patients and is characterized by proliferation and
accumulation of monoclonal B lymphocytes, expressing
CD5, CD20 and CD23 molecules [1,2]. The involvement
of central nervous system (CNS) is considered a rare
and aggressive complication. Nevertheless, autopsy stud-
ies suggest that it is much more common than supposed
in clinical practice [3-5]. Reske-Nielsen and co-workers
(1974) were one of the first groups to detect this CNS
infiltration. These authors observed neurologic infiltra-
tion in 10 advanced stage patients, in a total of 14 CLL
necropsies. However, none of them had any neurologic
symptoms [6].
In most studies, case presentations are presented
[7-10] whereas others emphasize the role of diagnostic* Correspondence: mariahelenaornellas@gmail.com
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unless otherwise stated.methods [11,12]. Our aim is to present a new case of
CLL with leptomeningeal involvement and also to make
a review of the literature, focusing studies where immu-
nophenotypic profile was performed.Case presentation
A 75-year-old mulatto woman was admitted to the Uni-
versity Hospital with a 2-week history of headache, otal-
gia in the right ear, fever, dizziness and dysphagia.
Physical examination showed diffuse lymphadenopathy,
gait instability, peripheral right-side facial nerve palsy
and incoordination of lower limbs. Muscle strength and
reflexes were normal in the upper limbs. Her medical
history was remarkable for hypertension, type 2 diabetes
mellitus and chronic lymphocytic leukemia (CLL), diag-
nosed five years earlier (Rai stage I with evolution to Rai
II with lymphocyte increasing and response to treat-
ment). She was no longer receiving treatment for this
disorder and the last chemotherapy had occurred five
months before. She had been treated before in threeal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phocytosis and liver and spleen enlargement, from June
to Sep 2005 (4 cycles) from Oct 2006 to June 2007 (8 cy-
cles) and from June 2008 to August 2009 (14 cycles).
Peripheral blood evaluation revealed leucocytosis
(white blood cell – WBC = 24.3×109/L), a mild anemia
(hemoglobin = 10.5 g/L) and 123×109 platelets/L, and
immunophenotypic study confirmed B-CLL. On the
biochemical examination, normal values of serum bili-
rubin, amylase, BUN, uric acid, albumin, transaminases,
calcium, potassium and iron were observed. As neuro-
logical examination had suggested a possible left brain
ischemia, computed tomography (CT) scan of the brain
was performed, but it was within normal limits. Mag-
netic resonance imaging (MRI) was recommended, but
the patient refused to do it because of claustrophobia.
Upper endoscopy was normal. Acute otitis media was
treated by myringotomy (showed serosanguineous fluid)
with clavulin and acyclovir.
An immediate lumbar puncture was performed and
the cerebrospinal fluid (CSF) revealed WBC count of 18
leukocytes/mm3 (mononuclear cells: 80%; polimorpho-
nuclear neutrophils: 20%), glucose of 92 mg/dL and total
protein of 50 mg/dL. GRAM, BAAR and criptococcal
were negative; bacteria, mycobacteria and fungi cultures;
and herpes virus in polymerase chain reaction (PCR)/
cryptococcal antigens were negative, VDRL and TPHA
negatives. Cytological examination of liquor showed typicalFigure 1 Cerebrospinal fluid and peripheral blood immunophenotypi
and peripheral blood (B) demonstrating CLL populations. The units on
in cerebrospinal fluid and peripheral blood cells, respectively. Four colour c
cytometry. The minority of cerebrospinal fluid cells were positive to double st
Ig lambda.and immunophenotypic analysis revealed small and mono-
morphic lymphocytes subset with profile: CD19+, CD5low
and lambda+, confirming CLL in CSF (Figure 1).
There was complete resolution of neurological symp-
toms liquor infiltration after 6 doses of weekly intrathecal
methotrexate and systemic fludarabine plus cyclophospha-
mide treatment. She was outpatient followed but died nine
months after, due to sepsis. Autopsy was not done.
Review of the literature of CLL cases involving CNS
The review of the literature was conducted according
Cochrane guidelines and Preferred Reporting Items
for Systematic Review and Meta-analysis recommen-
dations [13,14].
In December 13, 2013 the search was conducted in
PubMed Central (National Center for Biotechnology In-
formation, US National Library of Medicine, Washington).
In order to use search terminology Medical Subject
Headings (MeSH) headings was used. We conducted
two search strategies.
The MeSH terms used in the database search included:
Leukemia, Lymphoid/complications; Leukemia, Lymph-
oid/pathology; Brain Neoplasms/radiography; Leukemia,
Lymphoid/physiopathology; Leukemia, Lymphocytic,
Chronic, B-Cell/cerebrospinal fluid; Leukemia, Lympho-
cytic, Chronic, B-Cell/drug therapy; Leukemia, Lympho-
cytic, Chronic, B-Cell/radiotherapy; Leukemia, Lymphocytic,
Chronic, B-Cell/drug therapy; Lymphoma, B-Cell/ng: flow cytometric dot plots of cerebrospinal fluid (A, C and D)
the x- and y-axes are fluorescent intensitity. (A and B) CD5 XCD19
ytometry was performed using FACSCalibur (BD Biosciences) flow
aining showing in circle of the panel A. Panel C shows monoclonality to
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diagnosis; Central Nervous System Neoplasms/immunology.
For the second search strategy the term "Chronic
lymphocytic leukemia" was used in the search titles.
Studies were selected if they met the following inclu-
sion criteria:
1. Indexed articles between January 1st 1975 and
December 13th 2013;
2. The search included the follow documents: letters to
the editor, case presentations, case series, original
research reports and reviews;
3. Clinical research articles in adults;
4. The following idioms were included: English,
French, German and Spanish;
For exclusion criteria:
1. Articles published outside of proposed period;
2. Other published articles not specified by inclusion
criteria;Figure 2 Flow diagram representing the selection studies.3. Experimental clinical research articles;
4. Articles written by languages not specified by
inclusion criteria;
5. Ritcher syndrome.
Search results were merged using EndNote X7 (Thomson
Reuters, TX, USA) reference manager, and duplicate re-
cords removed. The titles and abstracts of the articles were
then examined and reports that were not randomized stud-
ies and those that were not relevant were removed.
All abstracts were independently reviewed by two au-
thors, and full texts were reviewed for determining eligi-
bility if abstracts were incomplete. Manuscripts that met
inclusion criteria were retained for full analysis. Any dis-
agreements were resolved by further discussion involving
an additional author.
The search identified 24,367 articles, of which 4,951
were removed for being duplicated. A total of 68 articles
were eligible satisfying established criteria for two research
strategies [2,5,7-10,15-79]. The flow diagram representing
the selection studies is shown in Figure 2.
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tients and those of the present case are summarized in
Table 1. More men than women were diagnosed with
CNS-CLL (male/female ratio: 1.77). The median time
for CNS disease was 29.5 months (ranging from 0 to
156 months), since CLL diagnosis. Positive cytology alone,
and with immunophenotyping analyses, was positive in 57
of 64 cases (89%). The majority of patients with available
clinical data were treated with intrathecal chemotherapy
and/or radiotherapy with systemic chemotherapy and
most of them demonstrated improvement in their symp-
tomatology. Neurological symptoms at presentation var-
ied. Visual changes occurred in one quarter of cases, with
or without other manifestations, such as slurred speech,
headaches, gait disorder and memory loss.
Conclusions
Chronic lymphocytic leukemia (CLL) involving the cen-
tral nervous system (CNS) presents with a high clinical
heterogeneity [80]. Some patients experiment a real indo-
lent course and have life expectancy similar to unaffected
individuals, while others have an aggressive malignancy
that requires early treatment and have limited survival.
As the disease progresses, lymphocytes infiltrate lymph
nodes, spleen and liver [81-83]. Occasionally, these cells
can infiltrate other organs, such as skin [84], lungs,
pleura, [85], gonads, prostate [86], kidneys [87] and
gastrointestinal tract [88]. Ratterman and colleagues
(2014) described in a recent systematic review about
extramedullary CLL, that CNS and skin were the most
frequently affected sites [81].
Including the present case, 92 patients have been de-
scribed with CNS-CLL in this review, and it provides the
largest summary of patients previously reported. Corrob-
orating other authors’ results, the current analysis sug-
gests that CNS-CLL is not as unusual as it seems
[2,80,81]. Nevertheless, CNS-CLL may be neglected for
several reasons, leading to improper and under-reported
diagnosis. Moreover, other neurological manifestations,
including opportunistic infections, secondary brain ma-
lignancies, therapy-related neurotoxicity, metabolic en-
cephalopathies and paraneoplastic neurologic syndromes,
were described in this entity [80]. Given the paucity of
reports describing central nervous system (CNS) in-
volvement, large scale investigations are complex and
challenging to perform and, consequently, the appropri-
ate identification and management of this disease are
hampered.
For the diagnosis evaluation, three parameters are
routinely used: (a) clinical signs and symptoms, (b) radio-
logical imaging, (c) cerebrospinal fluid (CSF) analysis.
Clinical manifestations ranged from the absence of
neurological signs, as described in autopsy series [5,89],
to a diverse and non-specific spectrum of symptoms(Table 1), which are common in this age group. Dementia,
gait disturbance, hearing loss and other neurologic symp-
toms are present in many diseases found in senescence.
Studies attempting to identify risk factors in patients who
develop CNS infiltration have failed in detecting common
predisposing conditions. A relevant number of patients
had the CNS involvement confirmation at the same time
of chronic lymphocytic leukemia diagnosis. In addition to
these in vivo findings, autopsy studies confirm that many
patients who had CNS involvement never referred neuro-
logical symptoms [3-6].
Radiologic findings (computed tomography [CT] and
magnetic resonance imaging [MRI]) of CNS involvement
have been described as diffuse coating of the leptomeninges
by a thin layer of leukemic cells, nodule growths, plaque-
like deposits and intraparenchymal infiltration [2,79].
However, cranial imaging has low sensibility in detect-
ing intracranial CLL, in comparison with other diseases
[90] and low specificity, as it may be misdiagnosed with
meningioma [15]. The present review confirms previous
studies, in which imaging investigation detected CNS
infiltration in approximately 40% of CLL cases [2,80].
Besides, in 4 cases of CSF negative for CLL infiltration,
radiologic imaging revealed brain masses [16-19].
Regarding the CSF analysis, the sample is obtained by
lumbar puncture and all precautions must be taken in
order to minimize contamination by peripheral blood.
This evaluation includes global and specific cell count,
glucose, total protein, culture and cytology. Although
CSF cytology examination is considered the “gold stand-
ard” for diagnoses, due to its excellent specificity (>95%),
its sensibility is within 50% to 60% [91].
Several variables associated with false negative cytology
have been identified [92], mainly due to the paucity of
tumor cells in CSF. Also, CLL lymphocytes can not be
distinguished from reactive lymphocytes by morphology
alone [93]. Reactive lymphocytes may be common in
these patients, who present immune suppression and
are susceptible to opportunistic infections.
Flow cytometry immunophenotyping (FCI) is an objective
and rapid method for qualitative and quantitative analysis
of cell suspensions. It can detect small populations of tumor
cells with aberrant surface-marker expression, through
multicolor and multiparameter analysis. FCI is considered
to be two to three times more sensitive than cytology in de-
tecting CSF malignant infiltration [2,11,12,80,92,94-96]. It is
particularly helpful for the detection of clonal popula-
tions of small sized B lymphocytes [97] which would
lead to the indication intrathecal chemotherapy and or
radiotherapy. The sensitivity of this technique can be
enhanced by cytocentrifuge methods as described by
Akintola-Ogunremi and coworkers (2002) [7].
Polymerase chain reaction (PCR) also known to im-
prove sensitivity in detecting CSF malignancy. However,
Table 1 Patient characteristics (N = 90)
Data





Missing data 4 (4)
Stage, N (%)
Rai 0,1 and Binet A 34 (38)
Rai 2 and Binet B 16 (18)
Rai 3,4 27 (30)
Missing data 13 (14)
Time to CNS disease, N (%)
Until 1 year 35 (39)
>1≤ 5 year 29 (33)
> 5 year 13 (14)
Missing data 13 (14)
CNS site of involvement, N (%)
Leptomeningeal 53 (59)
Leptomeningeal and brain parenchima 4 (5)





Missing data 44 (48)
Cerebrospinal fluid, N (%)
Positive 57 (63)
Negative 7 (8)
Missing data 26 (29)
Histology, N (%)
Yes (positive) 15 (17)
No 75 (83)
Treatment
IT + systemic chemotherapy 17 (19)
IT + radiation therapy 13 (14)
IT chemotherapy 13 (14)
IT + systemic + radiation therapy 8 (9)
Systemic chemotherapy 8 (9)
Systemic + radiation therapy 6 (7)
Radiation therapy 5 (6)
None 9 (10)
Not available 11 (12)
Table 1 Patient characteristics (N = 90) (Continued)
Survival status, N (%)
Alive 38 (42)
Dead 38 (42)
Missing data 14 (16)
IT = intrathecal treatment.
ahypothalamus, optic nerve, pituitary, skull base thickening, spinal cord, dura
mater, epidural.
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selection of specific tumor cell primers. Therefore its
routine employment continues to be restricted [98].
Vogt-Schaden and colleagues (1999) confirmed lepto-
meningeal dissemination in a patient with CLL using a
clone-specific CDR3 region in IgH encoding locus. It
has already been reported in a study about lymphomas
and reactive lymphoid proliferations that the use of both
FCI and PCR techniques in different sample specimens
[77]. The authors observed a superior sensitivity of FCM
when compared with PCR (77% vs 64%). However, they
concluded that combined use should be considered as
the sensitivity reached to 93% [99].
The identification of specific tumor markers for CNS
leukemic invasion has remained elusive. Soluble CD27
(sCD27) was already considered a probable marker for
leptomeningeal involvement. Van den Bent and coworkers
(2002) [100] demonstrated that it was useful in ruling out
the disease with a negative predictive value of 92%. Never-
theless sCD27 was also detected in various non-malignant
inflammatory conditions (positive predictive value = 54%).
Although larger prospective studies with longer follow-
up are required, we suggest that patients should be care-
fully evaluated for more precise evidence of CNS lymphoid
malignancies before receiving toxic treatments. In addi-
tion mentioning Pirandello’s masterpiece “So It Is (If
You Think So)” clinicians should use all possible diag-
nostic tools to identify CNS infiltration in CLL. After
this systematic review, we can conclude that the early
identification of the central nervous system involvement
and prompt treatment should be considered to reduce
morbidity and improve quality of life of these patients.Consent
Written informed consent was obtained from the patient
for publication of this Case presentation and any accom-
panying images. A copy of the written consent is avail-
able for review by the Editor-in-Chief of this journal.Abbreviations
B-CLL: B-cell chronic lymphocytic leukemia; CD: Cluster of differentiation;
CNS: Central nervous system; WBC: White blood cell; BUN: Blood urea
nitrogen; CT: Computed tomography; MRI: Magnetic resonance imaging;
CSF: Cerebrospinal fluid; FCI: Flow cytometry immunophenotyping;
PCR: Polymerase chain reaction; sCD27: Soluble CD27.
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